Your browser doesn't support javascript.
loading
Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.
Zhang, Bo; Yan, You-You; Gu, Yang-Qin; Teng, Fei; Lin, Xu; Zhou, Xing-Lu; Che, Jin-Xin; Dong, Xiao-Wu; Zhou, Li-Xin; Lin, Neng-Ming.
Affiliation
  • Zhang B; College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
  • Yan YY; Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Gu YQ; College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
  • Teng F; Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Lin X; College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
  • Zhou XL; Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Che JX; College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
  • Dong XW; Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Zhou LX; Department of Thoracic Surgery, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
  • Lin NM; Hangzhou Hezheng Pharmaceutical Co. Ltd, Hangzhou, Zhejiang, China.
J Cell Mol Med ; 26(2): 515-526, 2022 01.
Article de En | MEDLINE | ID: mdl-34921503
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Ribosomal Protein S6 Kinases, 70-kDa Limites: Humans Langue: En Journal: J Cell Mol Med Sujet du journal: BIOLOGIA MOLECULAR Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Ribosomal Protein S6 Kinases, 70-kDa Limites: Humans Langue: En Journal: J Cell Mol Med Sujet du journal: BIOLOGIA MOLECULAR Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni